Marshall Wace, LLP Arcellx, Inc. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Arcellx, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 15,400 shares of ACLX stock, worth $996,072. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,400

Holding current value

$996,072

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$60.26 - $79.13 $928,004 - $1.22 Million	15,400 New	15,400 $1.01 Million
Q1 2024 May 15, 2024	BUY	$51.85 - $73.49 $171,105 - $242,516	3,300 New	3,300 $229,000

Others Institutions Holding ACLX

# of Institutions

214

Shares Held

48.8M

Call Options Held

764K

Put Options Held

296K

Paradigm Biocapital Advisors LP New York, NY

4.49M
Shares

$291 Million
15.1% of portfolio
Vanguard Group Inc Valley Forge, PA

3.99M
Shares

$258 Million
0.0% of portfolio
Nea Management Company, LLC Timonium, MD

3.75M
Shares

$242 Million
23.3% of portfolio
Black Rock Inc. New York, NY

3.52M
Shares

$227 Million
0.0% of portfolio
Ra Capital Management, L.P. Boston, MA

3.04M
Shares

$196 Million
4.14% of portfolio

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.83B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account